Liquid Biopsy Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of Liquid Biopsy Market by product (CTCs and ctDNA and exosome), (clinical diagnostic laboratories, hospitals, and physician’s office laboratories) market status and outlook of global and major regions, from manufacturers, and end industries. As this report is expected to help key players among the Liquid Biopsy Market it includes the five years Industry analysis and the 6 years annual forecast from 2018 to 2024. Some of the prominent participants in the Global Liquid Biopsy Market are Mylan, LEO Pharma, Bayer HealthCare, Encore Dermatology, Novartis AG, Valent Pharmaceutical Inc., Astellas Pharma Inc., Meda AB, Valeant and Others. According to report the global liquid biopsy market is projected to grow at a CAGR of 21.1% over the forecast period of 2018-2024.
Get free Sample Pages of this Premium Report: – https://www.infiniumglobalresearch.com/reports/sample_request/1300
The analysis of non-solid biological tissue, mainly blood is known as liquid biopsy or as fluid biopsy. This type of technique is mainly used as a diagnostic and monitoring tool for diseases such as cancer. FDA has validated and approved liquid biopsy for circulating tumor cells as a useful prognostic method for various types of cancer. Liquid biopsy tests are done to understand the molecular aspects of cancer across the healthcare and research settings, such as physicians, pathological, hospitals, and research laboratories. It is a harmless blood test that will not damage the healthy tissues .The researchers, physicians, and surgeons get appropriate data about patient’s cancer condition, with the help of this test appropriate therapy is provided to improve the survival rate of the cancer patients.
The increasing incidences of the cancer worldwide is likely to drive the growth of the market. Additionally, easy and non-invasive entrance to the tumor genome, early cancer diagnosis & detection and technology advancement and novel clinical trials for research and development is likely to propel the growth of the market. On the other hand, the lack of skilled professional to take the blood sample is likely to hamper the growth of the market. In addition, the reimbursement of medical costs and changing governmental policies are likely to restraint the growth of the market.
Among the geographies, North America is expected to be largest market for liquid biopsy followed by Europe due to recent regulatory approvals by CE for commercial use of liquid biopsy tests in this region. In addition, adoption of technologically advanced products and increasing research and development funding/investments is likely to drive the growth in this region. While, Asia-Pacific is expected to grow fast during the forecast period, owing to rising prevalence of different cancer types, and growth in per capital health expenditure in countries like China and India is likely to augment the growth in this region.
The report on global liquid biopsy market covers segments such as, product. On the basis of product the global liquid biopsy market is categorized into (CTCs and ctDNA and exosome. On the basis of end-user the global liquid biopsy market is categorized into clinical diagnostic laboratories, hospitals, and physician’s office laboratories.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section the key trends and market size for each geography is provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience a growth at a CAGR of x.x% over the period of 2018-2024.
Major Key Players Mentioned in this Premium Report
The report provides profiles of the companies in the global liquid biopsy market such as Exosome Diagnostics, Roche Molecular Diagnostics, QIAGEN, Thermo Fisher Scientific, CellMax Life, Chronix Biomedical, Epic Sciences, Bio-Rad Laboratories, Agena Bioscience, RainDance Technologies
The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the global liquid biopsy market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter’s five forces analysis and DRO analysis of liquid biopsy market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the liquid biopsy market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. This report will help manufacturers, suppliers and distributors of the liquid biopsy market to understand the present and future trends in this market and formulate their strategies accordingly.